Plain-English translation of NCT07796113 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new combination treatment for esophageal squamous cell carcinoma (a type of esophageal cancer) that has spread to nearby lymph nodes or tissues. The treatment includes three components: adebrelimab, famitinib, and standard chemotherapy drugs (paclitaxel and cisplatin). Patients receive this medication combination before surgery to try to shrink the cancer as much as possible.
Esophageal cancer is a serious disease, and doctors are looking for better ways to treat it before surgery. This trial is exploring whether combining this new immunotherapy medication with targeted therapy and chemotherapy can be more effective at eliminating cancer cells than traditional treatment alone.
You likely qualify if…
You likely don't qualify if…
You would receive the medication combination every 3 weeks for 2 cycles (6 weeks total). Each treatment day, you would receive intravenous infusions of the three medications in sequence, with breaks between each infusion. Additionally, you would take one of the medications as a pill at home for 2 weeks of each 3-week cycle. After completing these 6 weeks of treatment, your cancer would be reassessed, and if it has responded well, you would proceed to surgery. Throughout the trial, you would have regular blood tests and scans to monitor how the treatment is working and to watch for any side effects.
AI-generated summary from trial data · Sep 16, 2026 · Not medical advice
China